Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 789136, 10 pages
http://dx.doi.org/10.1155/2015/789136
Research Article

Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy

1Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
2Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, Duke University Medical Center, Durham, NC 27710, USA
3Duke University, Durham, NC 27710, USA
4Duke University School of Medicine, Durham, NC 27710, USA
5Division of Experimental Medicine, Merck, Rahway, NJ 07065, USA
6Durham VA Medical Center, Section of Otolaryngology-Head and Neck Surgery, Durham, NC 27705, USA

Received 28 August 2015; Accepted 8 October 2015

Academic Editor: Roberta Castriconi

Copyright © 2015 Jens Dannull et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. Curtsinger, D. C. Lins, and M. F. Mescher, “Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function,” Journal of Experimental Medicine, vol. 197, no. 9, pp. 1141–1151, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. C.-S. Hsieh, S. E. Macatonia, C. S. Tripp, S. F. Wolf, A. O'Garra, and K. M. Murphy, “Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages,” Science, vol. 260, no. 5107, pp. 547–548, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Galea-Lauri, J. W. Wells, D. Darling, P. Harrison, and F. Farzaneh, “Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination,” Cancer Immunology, Immunotherapy, vol. 53, no. 11, pp. 963–977, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. R. M. Steinman and J. Banchereau, “Taking dendritic cells into medicine,” Nature, vol. 449, no. 7161, pp. 419–426, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. W. T. Lee, K. Shimizu, H. Kuriyama, H. Tanaka, J. Kjaergaard, and S. Shu, “Tumor-dendritic cell fusion as a basis for cancer immunotherapy,” Otolaryngology—Head and Neck Surgery, vol. 132, no. 5, pp. 755–764, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Shu, R. Zheng, W. T. Lee, and P. A. Cohen, “Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy,” Critical Reviews in Immunology, vol. 27, no. 5, pp. 463–483, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Homma, T. Kikuchi, N. Ishiji et al., “Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12,” European Journal of Clinical Investigation, vol. 35, no. 4, pp. 279–286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Kuriyama, K. Shimizu, W. Lee et al., “Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells,” Developments in Biologicals, vol. 116, pp. 169–186, 2004. View at Google Scholar · View at Scopus
  10. H. Zhang, K. M. Snyder, M. M. Suhoski et al., “4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy,” The Journal of Immunology, vol. 179, no. 7, pp. 4910–4918, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Zheng, P. A. Cohen, C. A. Paustian et al., “Paired toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12,” Cancer Research, vol. 68, no. 11, pp. 4045–4049, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. B. D. Car, V. M. Eng, J. M. Lipman, and T. D. Anderson, “The toxicology of interleukin-12: a review,” Toxicologic Pathology, vol. 27, no. 1, pp. 58–63, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Tan, J. Dannull, S. K. Nair et al., “Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination,” Journal of Surgical Research, vol. 185, no. 2, pp. 904–911, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. E. I. Cho, C. Tan, G. K. Koski, P. A. Cohen, S. Shu, and W. T. Lee, “Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines,” Head and Neck, vol. 32, no. 6, pp. 700–707, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. L. Gaffen, “Structure and signalling in the IL-17 receptor family,” Nature Reviews Immunology, vol. 9, no. 8, pp. 556–567, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. N. L. Tran, W. S. McDonough, B. A. Savitch, T. F. Sawyer, J. A. Winkles, and M. E. Berens, “The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression,” The Journal of Biological Chemistry, vol. 280, no. 5, pp. 3483–3492, 2005. View at Publisher · View at Google Scholar
  17. J. Skonier, K. Bennett, V. Rothwell et al., “βig-h3: a transforming growth factor-β-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice,” DNA and Cell Biology, vol. 13, no. 6, pp. 571–584, 1994. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Zou, G. Levy-Cohen, and M. Blank, “Molecular functions of NEDD4 E3 ubiquitin ligases in cancer,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1856, no. 1, pp. 91–106, 2015. View at Publisher · View at Google Scholar
  19. A. Paun and P. M. Pitha, “The IRF family, revisited,” Biochimie, vol. 89, no. 6-7, pp. 744–753, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. K. S. Wang, D. A. Frank, and J. Ritz, “Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4,” Blood, vol. 95, no. 10, pp. 3183–3190, 2000. View at Google Scholar · View at Scopus
  21. V. Bours, P. R. Burd, K. Brown et al., “A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site,” Molecular and Cellular Biology, vol. 12, no. 2, pp. 685–695, 1992. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Galibert, M. E. Tometsko, D. M. Andersen, D. Cosman, and W. C. Dougall, “The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF- κB, a member of the TNFR superfamily,” Journal of Biological Chemistry, vol. 273, no. 51, pp. 34120–34127, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Sallusto, D. Lenig, C. R. Mackay, and A. Lanzavecchia, “Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes,” The Journal of Experimental Medicine, vol. 187, no. 6, pp. 875–883, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Muthuswamy, J. Urban, J.-J. Lee, T. A. Reinhart, D. Bartlett, and P. Kalinski, “Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation,” Cancer Research, vol. 68, no. 14, pp. 5972–5978, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Dannull, T. Schneider, W. T. Lee, N. De Rosa, D. S. Tyler, and S. K. Pruitt, “Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function,” Blood, vol. 119, no. 13, pp. 3113–3122, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. L. A. Garraway and W. R. Sellers, “Lineage dependency and lineage-survival oncogenes in human cancer,” Nature Reviews Cancer, vol. 6, no. 8, pp. 593–602, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. S. G. Slutsky, A. K. Kamaraju, A. M. Levy, J. Chebath, and M. Revel, “Activation of myelin genes during transdifferentiation from melanoma to glial cell phenotype,” The Journal of Biological Chemistry, vol. 278, no. 11, pp. 8960–8968, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Botti, G. Scognamiglio, L. Marra et al., “SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression,” Virchows Archiv, vol. 465, no. 3, pp. 331–338, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Abdollahi, D. Pisarcik, D. Roberts, J. Weinstein, P. Cairns, and T. C. Hamilton, “LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer,” Journal of Biological Chemistry, vol. 278, no. 8, pp. 6041–6049, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Nusse and H. Varmus, “Three decades of Wnts: a personal perspective on how a scientific field developed,” The EMBO Journal, vol. 31, no. 12, pp. 2670–2684, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Wang, Z. Z. Chong, Y. C. Shang, and K. Maiese, “Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL,” Current Neurovascular Research, vol. 9, no. 1, pp. 20–31, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. M. E. Conacci-Sorrell, T. Ben-Yedidia, M. Shtutman, E. Feinstein, P. Einat, and A. Ben-Ze'ev, “Nr-CAM is a target gene of the β-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis,” Genes & Development, vol. 16, no. 16, pp. 2058–2072, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Liu, J. O. Farmer Jr., W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber, “Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes,” Cell, vol. 66, no. 4, pp. 807–815, 1991. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Schmitz, “Gadd45 proteins in immunity,” Advances in Experimental Medicine and Biology, vol. 793, pp. 51–68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. N. L. Malinin, M. P. Boldin, A. V. Kovalenko, and D. Wallach, “MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1,” Nature, vol. 385, no. 6616, pp. 540–544, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Dickens, J. S. Rogers, J. Cavanagh et al., “A cytoplasmic inhibitor of the JNK signal transduction pathway,” Science, vol. 277, no. 5326, pp. 693–696, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Harizi, M. Juzan, V. Pitard, J.-F. Moreau, and N. Gualde, “Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10, which down-regulates dendritic cell functions,” The Journal of Immunology, vol. 168, no. 5, pp. 2255–2263, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Kaliriski, P. L. Vieira, J. H. N. Schuitemaker, E. C. de Jong, and M. L. Kapsenberg, “Prostaglandin E2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer,” Blood, vol. 97, no. 11, pp. 3466–3469, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. A. E. Ryan, F. Shanahan, J. O'Connell, and A. M. Houston, “Addressing the ‘Fas counterattack’ controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo,” Cancer Research, vol. 65, no. 21, pp. 9817–9823, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. D. P. McLornan, H. L. Barrett, R. Cummins et al., “Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer,” Clinical Cancer Research, vol. 16, no. 13, pp. 3442–3451, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Fourcade, P. Kudela, Z. Sun et al., “PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients,” Journal of Immunology, vol. 182, no. 9, pp. 5240–5249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Nicolini, A. Carpi, and G. Rossi, “Cytokines in breast cancer,” Cytokine and Growth Factor Reviews, vol. 17, no. 5, pp. 325–337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. A. M. Jackson, L. A. Mulcahy, W. Z. Xing, D. O'Donnell, and P. M. Patel, “Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation,” International Journal of Cancer, vol. 123, no. 3, pp. 623–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Gosset, F. Bureau, V. Angeli et al., “Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells,” Journal of Immunology, vol. 170, no. 10, pp. 4943–4952, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. P. A. Ott and N. Bhardwaj, “Impact of MAPK pathway activation in BRAFV600 melanoma on T cell and dendritic cell function,” Frontiers in Immunology, vol. 4, article 346, 2013. View at Publisher · View at Google Scholar
  46. V. O. Melnikova, S. V. Bolshakov, C. Walker, and H. N. Ananthaswamy, “Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines,” Oncogene, vol. 23, no. 13, pp. 2347–2356, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Fukazawa and Y. Uehara, “U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways,” Cancer Research, vol. 60, no. 8, pp. 2104–2107, 2000. View at Google Scholar · View at Scopus
  48. M. Cully, H. You, A. J. Levine, and T. W. Mak, “Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis,” Nature Reviews Cancer, vol. 6, no. 3, pp. 184–192, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. J.-W. Han, R. B. Pearson, P. B. Dennis, and G. Thomas, “Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites,” The Journal of Biological Chemistry, vol. 270, no. 36, pp. 21396–21403, 1995. View at Publisher · View at Google Scholar · View at Scopus